However, only a single report of thyroid hyperplasia and neoplasm AE (thyroid cancer) was observed in the metformin monotherapy cohort, and only 7 were observed in the SGLT-2 inhibitor monotherapy cohort that was selected as the control due to similar T2DM disease-stage treatment guideline recommendations. The gene discussed is SLC5A2; the disease is thyroid cancer.